![](https://www.diabetesnews.com/wp-content/uploads/2015/07/stomach-acid-810x400-150x150.jpg)
A new treatment called endoscopic duodenal mucosal resurfacing (DMR), combined with a glucagon-like peptide (GLP)-1 receptor agonist medication, has been shown to improve glycemic control in patients with type 2 diabetes, and possibly could enable them to discontinue insulin therapy. Read more